Clinical Trial Update: Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a dose-cycle regimen of Imiquimod for actinic keratosis has completed with safety and efficacy outcomes reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• Imiquimod (imiquimod)

Snippet

Sponsor: University of British Columbia | Conditions: Actinic Keratoses | Phase 3 | Status: COMPLETED